Editor's Note: In response to reader demand, the story has been updated with a chart highlighting the drug approval predictions of the contest's leading contestants to date.
Jim Cramer is bullish on Nektar Therapeutics and Alkermes, as well as Verizon and Bank of America.
Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.
The firms all have drugs they want the feds to bend the rules to approve.
Nine biotech and drug companies want FDA approval, but need changed standards to get it.